Pioglitazone (Piog) is a member of thiazolidinediones, insulin-sensitizing drugs, which improve insulin sensitivity and dyslipidemia in type 2 diabetics (Ding et al. 2005). This evidence concerns the gene INS and type 2 diabetes mellitus.